Overview


According to FutureWise analysis the market for Clinical Mass Spectrometry in 2023 is US$ 1.23 billion, and is expected to reach over US$ 1.90 billion by 2031 at a CAGR of 6.40%.

Clinical mass spectrometry is widely used in research and special clinical laboratories, and its use in normal laboratories is rapidly rising. Mass spectrometry can determine which molecules make up a sample by measuring the spectrum created by the ions within it. Clinical mass spectrometry utilises mass spectrometry for diagnostic purposes. Medical laboratories use clinical mass spectrometry to diagnose metabolic disorders, look for biomarkers or enzymes, and perform toxicology tests. A clinical diagnostic mass spectrometer can analyse a small number of samples at once for a wide range of purposes. As a result, it is an extremely useful tool for diagnostic medical laboratories. One of the new ways to detect small quantities of proteins and biomarkers in clinical mass spectrometry is to measure their concentration even when they are very small.

One of the new applications of clinical mass spectrometry is the quantitative detection of low concentrations of proteins, biomarkers, or drug molecules. Researchers have been able to determine the pharmacokinetic characteristics of medications that have been administered in micro doses thanks to the availability of small samples with low concentrations. This protects against potential drug side effects while enabling researchers to learn how the drug interacts with the body. Clinical mass spectrometry's tiny sample and concentration requirements have also made it simpler to obtain information particular to paediatric patients, who occasionally cannot offer a large enough sample for conventional analysis techniques.

Some of the most common applications of mass spectrometry (MS) in the pharmaceutical and biotech industries are drug discovery, pharmacokinetics, proteomics, and metabolomics. Clinical research laboratories, diagnostic centres and many other perform analytical tests on specimens in order to determine disease diagnoses and locate responsible microorganisms. Increasing use of mass spectrometry in the field of diagnostics and in healthcare facilities is growing rapidly leading towards market growth. MS is considered as an effective analytical tool with high specificity and sensitivity. MS has become popular as a method for handling clinical samples with complex matrices, such as tissues and biofluids. It offers high-quality quantitative analysis even at low concentrations. However, the precise sample preparation or purification techniques required for chromatography-based approaches demand a lot of time and labour, and the specialised equipment needed for high-performance analysis is expensive. The on-site clinical translation of MS is significantly hampered by technical barriers and the high cost of MS. The aforementioned elements may hinder the target market. Technological advancement in the clinical field using mass spectrometry like MS based devices for diagnostic tests as well as for the identification of biomarkers have been made. Also, the prevalence of modern medicine is increasing using the mass spectrometry method to develop precision medicine (PM), which investigates a patient's genotype and phenotype to establish individually tailored drug treatment. Such technological advancement in the field of clinical mass spectrometry can provide key players with opportunities to increase their respective product portfolio in order to secure a higher customer base, further boost the revenue growth prospects for this target market.

FutureWise Market Research has published a report that provides an insightful analysis of clinical mass spectrometry market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, the clinical mass spectrometry market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Thermo Fisher Scientific Inc.
  • Agilent Technologies
  • Danaher Corporations
  • Waters
  • Perkin Elmer
  • Shidmazu
  • Bruker Corporation
  • Kore Technology Limited
  • Bergmann Messgeräte Entwicklung Kg
  • Mass Spectrometry Instruments (MSI)

(Note: The list of the major players will be updated with the latest market scenario and trends)

Some of the most common applications of mass spectrometry (MS) in the pharmaceutical and biotech industries are drug discovery, pharmacokinetics, proteomics, and metabolomics. Clinical research laboratories, diagnostic centres and many other perform analytical tests on specimens in order to determine disease diagnoses and locate responsible microorganisms. Increasing use of mass spectrometry in the field of diagnostics and in healthcare facilities is growing rapidly leading towards market growth. MS is considered as an effective analytical tool with high specificity and sensitivity. MS has become popular as a method for handling clinical samples with complex matrices, such as tissues and biofluids. It offers high-quality quantitative analysis even at low concentrations. However, the precise sample preparation or purification techniques required for chromatography-based approaches demand a lot of time and labour, and the specialised equipment needed for high-performance analysis is expensive. The on-site clinical translation of MS is significantly hampered by technical barriers and the high cost of MS. The aforementioned elements may hinder the target market. Technological advancement in the clinical field using mass spectrometry like MS based devices for diagnostic tests as well as for the identification of biomarkers have been made. Also, the prevalence of modern medicine is increasing using the mass spectrometry method to develop precision medicine (PM), which investigates a patient's genotype and phenotype to establish individually tailored drug treatment. Such technological advancement in the field of clinical mass spectrometry can provide key players with opportunities to increase their respective product portfolio in order to secure a higher customer base, further boost the revenue growth prospects for this target market.

By Product Type

  • Gas Chromatography–Mass Spectrometry (GC-MS) Instrument
  • Liquid Chromatography–Mass Spectrometry (LC- MS) Instrument
  • MALDI-TOF Mass Spectrometer
  • Capillary Electrophoresis–Mass Spectrometry
  • Ion Mobility Spectrometry-Mass Spectrometry

By Application

  • Clinical Testing
  • Proteomics
  • Drug Discovery

By End User

  • Hospitals
  • Research Laboratories
  • Diagnostic Laboratories

By Region

  • North America
  • Latin America
  • Europe
  • Asia-Pacific
  • Middle East and Africa 

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022. Moreover, GC-MS and LC-MS have a market share of 24.2% and 17.5%, respectively, for their respective products in 2022. This is due to the region's market being driven by research and development activities as well as governmental support. For instance, the American Society for Mass Spectrometry and the Federation of Analytical Chemistry and Spectrometry Societies, both of which were established in 1969, have a combined membership of over 7,500 scientists who work to advance the clinical application of mass spectrometry and related topics in the academic, industrial, and governmental sectors. As a result, North America now has a rigorous research infrastructure that is helping the clinical mass spectrometry market expand there.

  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the Clinical Mass Spectrometry Market By Product Type, By Application, By End User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com.

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Clinical Mass Spectrometry Market Variables, Trends and Scope
    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Clinical Mass Spectrometry Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Clinical Mass Spectrometry Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Clinical Mass Spectrometry Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gas Chromatography–Mass Spectrometry (GC-MS) Instrument
        2. Liquid Chromatography–Mass Spectrometry (LC- MS) Instrument
        3. MALDI-TOF Mass Spectrometer
        4. Capillary Electrophoresis–Mass Spectrometry
        5. Ion Mobility Spectrometry-Mass Spectrometry

  • 8.   Clinical Mass Spectrometry Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinical Testing
        2. Proteomics
        3. Drug Discovery

  • 9.   Clinical Mass Spectrometry Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Research Laboratories
        3. Diagnostic Laboratories

  • 10.   North America Clinical Mass Spectrometry Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Clinical Mass Spectrometry Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Clinical Mass Spectrometry Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Clinical Mass Spectrometry Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Agilent Technologies
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Danaher Corporations
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Waters
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Perkin Elmer
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Shidmazu
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Bruker Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Kore Technology Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Bergmann Messgeräte Entwicklung Kg
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Mass Spectrometry Instruments (MSI)
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients